For what its worth, if I were to forecast the GenP
Post# of 11802
The diabetes arena has seen enough of the cheap Chinese products, and enough of the feature rich, over-priced meter entries from the Big 4, but the diabetes world has not seen (yet) an affordable feature rich meter along with a test strip that is a +/- 10% 97% of the time. That would make GenPrecis 33% better than everyone else.
Just my opinion. But GenPrecis could be a $15-$25 million cash sale product if it is licensed to a legit partner (hopefully my company who desperately needs a new and better product). Even more if GenPrecis is sold by its creators.
However, like I have said, technical innovation doesn't matter. Profits don't really matter. Having a once in a generation product doesn't matter. The only thing that matters is share price and message board posters have made that soooo clear.